| Literature DB >> 36080604 |
Nabil A Alhakamy1,2, Nimbagal Raghavendra Naveen3, Shashank Gorityala4, Mallesh Kurakula5, Khaled M Hosny1, Awaji Y Safhi6, Deena M Bukhary7, Haitham A Bukhary7, Fahad Y Sabei6, Rayan Y Mushtaq8, Samar S Murshid9.
Abstract
Mucoadhesive polymers have an essential role in drug localization and target-specific actions in oral delivery systems. The current work aims to develop and characterize a new mucoadhesive polysaccharide polymer (thiolated xanthan gum-TXG and S-Protected thiolated xanthan gum-STX) that was further utilized for the preparation of repaglinide mucoadhesive tablets. The thiolation of xanthan gum was carried out by ester formation through the reaction of the hydroxyl group of xanthan gum and the carboxyl group of thioglycolic acid. Synthesis of TXG was optimized using central composite design, and TXG prepared using 5.303 moles/L of TGA and 6.075 g/L of xanthan gum can accomplish the prerequisites of the optimized formulation. Consequently, TXG was further combined with aromatic 2-mercapto-nicotinic acid to synthesize STX. TXG and STX were further studied for Fourier-transform infrared spectroscopy, rheological investigations, and Ellman's assay (to quantify the number of thiol/disulfide groups). A substantial rise in the viscosity of STX might be due to increased interactions of macromolecules liable for improving the mucosal adhesion strength of thiolated gum. STX was proven safe with the support of cytotoxic study data. Mucoadhesive formulations of repaglinide-containing STX showed the highest ex vivo mucoadhesion strength (12.78 g-RSX-1 and 17.57 g- RSX-2) and residence time (>16 h). The improved cross-linkage and cohesive nature of the matrix in the thiolated and S-protected thiolated formulations was responsible for the controlled release of repaglinide over 16 h. The pharmacokinetic study revealed the greater AUC (area under the curve) and long half-life with the RSX-2 formulation, confirming that formulations based on S-protected thiomers can be favorable drug systems for enhancing the bioavailability of low-solubility drugs.Entities:
Keywords: mucoadhesion; repaglinide; tablet; thiolation; xanthan gum
Year: 2022 PMID: 36080604 PMCID: PMC9460926 DOI: 10.3390/polym14173529
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.967
Experimental plan for Box–Behnken design in terms of actual and coded values.
| Factors/Independent Variables | Levels | Responses/Dependent Variables | Constraints | ||||
|---|---|---|---|---|---|---|---|
| −1.414 | −1 | 0 | +1 | +1.414 | |||
| TGA Conc- X1 | 1.17 | 2 | 4 | 6 | 6.82 | Viscosity | Maximum |
| Xanthan Gum Conc-X2 (g/L) | 3.17 | 4 | 6 | 8 | 8.82 | MS (h) | Maximum |
Figure 1Schematic representation of synthesis of TXG and STX. (a) Synthesis of TXG using TGA and (b) synthesis of STX using M.A.
Formulation of repaglinide gastro retentive mucoadheisve tablets *.
| RXG-1 | RXG-2 | RTX-1 | RTX-2 | RSX-1 | RSX-2 | |
|---|---|---|---|---|---|---|
| Xanthan gum (%) | 30 | 60 | -- | -- | -- | -- |
| TXG (%) | -- | -- | 30 | 60 | -- | -- |
| STX (%) | -- | -- | -- | -- | 30 | 60 |
* Every formulation consists of repaglinide (10 mg), Magnesium stearate (4 mg), talc (4 mg) and microcrystalline cellulose (MCC)—an adequate amount to produce 150 mg tablet.
Experimental runs projected and their responses observed.
| Factor 1 | Factor 2 | Response 1 | Response 2 | ||
|---|---|---|---|---|---|
| Std | Run | A:TGA Conc | B:Xanthan Gum Conc | Viscosity | MS |
| (moles/L) | (g/L) | mPa-s | h | ||
| 1 | 13 | 2 | 4 | 15.5 | 2.5 |
| 3 | 1 | 2 | 8 | 17.5 | 2.9 |
| 5 | 10 | 1.17157 | 6 | 18.7 | 1.5 |
| 7 | 12 | 4 | 3.17157 | 20.4 | 3.8 |
| 8 | 9 | 4 | 8.82843 | 22.4 | 5.4 |
| 13 | 2 | 4 | 6 | 27.4 | 8.4 |
| 10 | 8 | 4 | 6 | 27.5 | 8.5 |
| 11 | 11 | 4 | 6 | 27.5 | 8.2 |
| 9 | 3 | 4 | 6 | 27.9 | 8.3 |
| 12 | 6 | 4 | 6 | 28.1 | 8.4 |
| 2 | 4 | 6 | 4 | 28.4 | 6.2 |
| 4 | 5 | 6 | 8 | 28.4 | 5.7 |
| 6 | 7 | 6.82843 | 6 | 34.5 | 4.6 |
Model statistical summary.
| Response | Models | R2 | Adju.R2 | Pred.R2 | Adequate Precision | Sequential | Remarks |
|---|---|---|---|---|---|---|---|
| Viscosity | Linear | 0.7398 | 0.6878 | 0.5335 | ---- | 0.0012 | |
| 2 FI | 0.7426 | 0.6568 | 0.3078 | ---- | 0.7636 | ||
| Quadratic | 0.9848 | 0.9740 | 0.8976 | 29.2120 | <0.0001 | Suggested | |
| Cubic | 0.9858 | 0.9659 | 0.1529 | --- | 0.8488 | Aliased | |
| MS | Linear | 0.2017 | 0.0421 | −0.2903 | --- | 0.3242 | |
| 2 FI | 0.2044 | −0.0608 | −0.6586 | --- | 0.8663 | ||
| Quadratic | 0.9763 | 0.9593 | 0.8351 | 20.2198 | <0.0001 | Suggested | |
| Cubic | 0.9928 | 0.9826 | 0.5796 | --- | 0.0514 |
Analysis of variance (ANOVA) results.
| Intercept | A | B | AB | A2 | B2 | |
|---|---|---|---|---|---|---|
| Viscosity | 27.68 | 5.76807 | 0.603553 | −0.5 | −0.9275 | −3.5275 |
| <0.0001 | 0.0061 | 0.2974 | 0.0283 | <0.0001 | ||
| MS | 8.36 | 1.36051 | 0.270343 | −0.225 | −2.53 | −1.755 |
| 0.0001 | 0.0017 | 0.4055 | <0.0001 | <0.0001 |
Figure 2Contour plots and 3-D response surface graphs for (a) viscosity and (b) MS.
Figure 3Desirability plot and optimized concentrations to prepare TXG (TGA conc—Moles/L; Xanthan Gum Conc—g/L; Viscosity—mPa-s; MS-h).
Figure 4FTIR spectra of xanthan gum, TXG and STX. (a) confirms the presence of thiol groups in TXG and STX and (b) represents the S-Protected groups of STX.
Figure 5Rheological profile of xanthan gum, TXG, and STX.
The quantity of thiol and disulfide groups was estimated by quantitative assay.
| Sample | -SH | -S-S- | MNA |
|---|---|---|---|
| (µmol/g) | |||
| TXG | 266.78 ± 13 | 202.29 ± 14 | -- |
| STX | -- | -- | 219.48 ± 11.8 |
Figure 6Assessment of the CSFR for prepared batches.
Figure 7Swelling studies of repaglinide mucoadhesive formulations.
Comparison of ex vivo mucoadhesion time and mucoadhesion strength.
| Ex Vivo Residence Time | Mucoadhesion Strength | ||
|---|---|---|---|
| Glass Slide Method | Modified Basket | (g) | |
| RXG-1 | 410 min | 385 min | 1.68 ± 0.85 |
| RXG-2 | 460 min | 442 min | 2.45 ± 1.12 |
| RTX-1 | 575 min | 559 min | 3.89 ± 1.35 |
| RTX-2 | 640 min | 635 min | 6.13 ± 2.04 |
| RSX-1 | >16 h | >16 h | 12.78 ± 1.45 |
| RSX-2 | >16 h | >16 h | 17.57 ± 1.28 |
Figure 8Cytotoxic studies.
Figure 9In vitro drug release profile of repaglinide mucoadhesive formulations. (CDR—cumulative drug release).
Figure 10A typical chromatogram of repaglinide by RP-HPLC.
Pharmacokinetic parameters for repaglinide solution and test (RSX-2) preparations.
| Pharmacokinetic Parameter | Pure Repaglinide | RSX-2 |
|---|---|---|
| Cmax (μg mL−1 h) | 0.313 ± 0.020 | 0.229 ± 0.015 |
| t max (h) | 1 ± 0.000 | 9.000 ± 0.000 |
| AUC0-t (μg mL−1 h) | 0.395 ± 0.251 | 2.865 ± 0.084 |
| AUMC0-t (μg mL−1 h) | 0.49 ± 0.321 | 25.481 ± 1.249 |
| MRTt (h) | 1.25 ± 0.268 | 10.746 ± 0.142 |
| t1/2 (h) | 0.41 ± 0.084 | 4.587 ± 0.247 |
| AUC0-i (μg mL−1 h) | 0.396 ± 0.0.324 | 2.905 ± 0.128 |
| AUMC0-i (μg mL−1 h) | 0.496 ± 0.415 | 27.645 ± 1.089 |
| CL (l/h) | 2.52 ± 0.159 | 0.801 ± 0.031 |
| Vd (l) | 1.48 ± 0.098 | 2.948 ± 0.391 |
| Ke (1/h) | 1.690 | 0.252 |
Figure 11Plasma concentration–time profile for RSX-2 and pure repaglinide (n = 6).